Breast Cancer: Recurrent Genomic Alterations: Difference between revisions
| [unchecked revision] | [unchecked revision] |
Kgeiersbach (talk | contribs) No edit summary |
Kgeiersbach (talk | contribs) No edit summary |
||
| Line 306: | Line 306: | ||
|amplification, altered expression, sequence variants | |amplification, altered expression, sequence variants | ||
|Disease: metastatic BC; overexpression associated with poor prognosis; Therapy: resistance to CDK4/6 inhibitors. Additionally, CCNE1 amplification or activating mutations may be sensitive to inhibitors of Cdk2, the protein that Cyclin E1 binds and activates. Other potential therapies include combined Cdk and Akt or PI3K inhibitors, and Wee1 inhibitors. | |Disease: metastatic BC; overexpression associated with poor prognosis; Therapy: resistance to CDK4/6 inhibitors. Additionally, CCNE1 amplification or activating mutations may be sensitive to inhibitors of Cdk2, the protein that Cyclin E1 binds and activates. Other potential therapies include combined Cdk and Akt or PI3K inhibitors, and Wee1 inhibitors. | ||
|[https://pubmed.ncbi.nlm.nih.gov/30807234/ 30807234]; [https://pubmed.ncbi.nlm.nih.gov/30665374/ 30665374]; [https://pubmed.ncbi.nlm.nih.gov/32885893/ 32885893]; [https://pubmed.ncbi.nlm.nih.gov/35005994/ 35005994]; [https://pubmed.ncbi.nlm.nih.gov/23185313/ 23185313] | |[https://pubmed.ncbi.nlm.nih.gov/40243688/ 40243688];[https://pubmed.ncbi.nlm.nih.gov/30807234/ 30807234]; [https://pubmed.ncbi.nlm.nih.gov/30665374/ 30665374]; [https://pubmed.ncbi.nlm.nih.gov/32885893/ 32885893]; [https://pubmed.ncbi.nlm.nih.gov/35005994/ 35005994]; [https://pubmed.ncbi.nlm.nih.gov/23185313/ 23185313] | ||
|- | |- | ||
|''CD274'' | |''CD274'' | ||